Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5510050 | 1.00 | HTR2A (0.33) | HTR2AHTR2CHTR2BKDM4EALDH1A1 | |
| SCHEMBL5510047 | 1.00 | HTR2A (0.33) | HTR2AHTR2CHTR2BKDM4EALDH1A1 | |
| SCHEMBL4198062 | 0.80 | HTR1A (0.37) | KDM4EALDH1A1 | |
| SCHEMBL5507570 | 0.80 | HTR1A (0.37) | KDM4EALDH1A1 | |
| SCHEMBL5507571 | 0.80 | HTR1A (0.37) | KDM4EALDH1A1 | |
| SCHEMBL4198061 | 0.80 | HTR1A (0.37) | KDM4EALDH1A1 | |
| SCHEMBL4198060 | 0.80 | HTR1A (0.37) | KDM4EALDH1A1 | |
| SCHEMBL17785902 | 0.69 | HTR2A (0.53) | HTR2AHTR2CHTR2BALDH1A1CA1 | |
| SCHEMBL14095798 | 0.68 | PNMT (0.37) | HTR2AHTR2CHTR2BCA1CA2 | |
| SCHEMBL5047298 | 0.68 | TP53 (0.35) | HTR2AHTR2CHTR2BCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254917-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INC. | 2007-11-01 | — | — | US | disclosed |
| EP-1778233-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006019716-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254917-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | CASR, GRK2, RYR2 | HTR2A 515/4885HTR2C 583/4885HTR2B 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.